Glimpse at the complexity of drug prices
I feel that there is considerable confusion about drug prices amongst industry outsiders. Until I started looking into the topic, I had no idea how complex it was.
Economics to boost antibiotics development
Considering the importance of antibiotics for our healthcare, the issue of a dwindling development pipeline must be addressed. This article outlines various economic suggestions.
Will bonding curves be researchers’ best friends?
Continuous token bonding curves, formerly referred to as curation markets, describe a blockchain framework that is different from the concept underlying the now widely known cryptocurrency Bitcoin.
Paying for patient expertise
Scientists in academic or other institutions use the unique insights patients provide to inform their research. Pharmaceutical companies oftentimes look for customer input primarily in late development stages. So far however, their main focus has been on physicians. Working with all stakeholders, including patients, early in the R&D process can help make it more productive and lower development costs by […]
Justifying health insurance expenditure
It can be difficult for public health insurers to decide which medical interventions to cover. After all, it is the tax payers’ money that must be spent wisely and equitably across all patient groups.
Gender transition is in transition
Transgender health management has seen important advances in the recent past. Some notable remaining issues revolve around the standard of care and insurance coverage.
What I want to do with Blue Steens
In my first ever vlog I give you a bit of background on myself and Blue Steens’ current incarnation. By the way, I am totally out of my comfort zone in front of a camera. Nothing like a new challenge…
Organ donation part 3/4 – The futures that never happened
Futures contracts for donations after death appear to ease major ethical concerns in the debate about payment for human organs. Yet, such proposals are incompatible with current law.